Sustained Therapeutics – Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual...
Sustained Therapeutics presented Phase 2 data showing its ST‑01 polymer‑lidocaine formulation significantly reduced pain in men with chronic scrotal content pain (CSCP). At the 70 mg/mL dose, 67% of patients achieved a ≥2‑point pain reduction and 83% met clinical response criteria, far outperforming standard lidocaine blocks. The trial enrolled 63 participants across eight Canadian sites and demonstrated durable, well‑tolerated effects over repeated monthly dosing. The company now aims to move ST‑01 into Phase 3 to address a sizable unmet market.
BIOTECanada Statement on Canada–Mexico Life Sciences Collaboration
BIOTECanada signed two memoranda of understanding with Mexico’s Asociación Mexicana de Laboratorios Farmacéuticos (AMILAF) and La Cámara Nacional de la Industria Farmacéutica (CANIFARMA), marking a new phase of life‑sciences collaboration. The MoUs were part of Mexico’s trade mission to Canada,...
AbbVie in Canada Appoints Tanu Misra as Vice President and General Manager
AbbVie announced Tanu Misra as Vice President and General Manager of its Canadian operations. Misra, who joined AbbVie in 2012, previously led the U.S. Dermatology Psoriatic and Immunology businesses, driving sustained growth. Before AbbVie she spent over a decade at...
BIOTECanada Responds to CDA-AMC Guidance for Incorporating Impacts on Informal Caregivers and Productivity Outcomes in Economic Evaluations.
BIOTECanada, together with Innovative Medicines Canada, submitted a formal response to the Canadian Drug Agency’s draft guidance on incorporating informal caregiver health‑related quality of life and productivity outcomes into economic evaluations. The association recommends expanding the societal perspective to all...
Canada’s Life Sciences Sector Welcomes Federal Economic Update’s Focus on SR&ED Implementation
BIOTECanada welcomed the 2026 Spring Economic Update, which confirms the rollout of SR&ED administrative reforms first announced in Budget 2025. The changes raise the annual expenditure limit and taxable‑capital phase‑out thresholds for the enhanced 35% credit, extend the credit to...
BIOTECanada Responds to Health Canada’s Gazette on Modernizing Clinical Trials Regulations
Health Canada has released a Gazette notice proposing modernized clinical‑trial regulations and draft guidance for decentralized trials. BIOTECanada welcomed the initiative but urged that the new rules align with the U.S. FDA and European EMA to avoid duplicative requirements. The...
BIOTECanada Responds to Health Canada’s Gazette on a Draft Order Providing for Reliance on International Regulatory Authorities
Health Canada’s Gazette released a draft Order that would allow Canadian regulators to rely on approvals from trusted foreign agencies, a key component of the Red Tape Review initiative. BIOTECanada praised the proposal, calling it a meaningful step toward faster...
National Immunization Awareness Week
National Immunization Awareness Week highlights the critical role of vaccines in safeguarding public health and easing pressure on health systems. The campaign underscores both routine immunizations and ongoing preparedness initiatives. BIOTECanada’s Vaccine Industry Committee (VIC) showcases Canada’s leading vaccine manufacturers...
Aspect Biosystems – Announces $280 Million Partnership with Government of Canada to Advance Development of Bioengineered Cellular Medicines
Aspect Biosystems secured a CAD $79 million (≈ $58 million USD) investment from the Government of Canada, funding a CAD $280 million (≈ $204 million USD) multi‑year project to accelerate its bioengineered cellular medicines pipeline. The funding builds on a prior CAD $200 million (≈ $146 million USD) co‑investment announced in 2024 and will expand...
GlycoNet – Sugar-Based Vaccine Against Bacterial Diarrhea Shows Promise in Phase 1 Trial
Researchers at the University of Guelph announced that their sugar‑based vaccine candidate against Campylobacter jejuni demonstrated safety and immunogenicity in a small Phase 1 human trial. Participants experienced only mild side effects, and the formulation generated measurable antibody responses even at...
BIOTECanada Welcomes the Announcement of the Pharmaceutical and Life Sciences Sector Task Force
BIOTECanada has praised the federal government’s launch of the Pharmaceutical and Life Sciences Sector Task Force, signaling a strategic push to strengthen Canada’s biotech and pharma ecosystem. The task force is tasked with reviewing investment incentives, regulatory frameworks, and market...
Eurofins CDMO Alphora – Announces Development & Implementation of AI-Powered Salt and Co-Crystal Screening Software
Eurofins CDMO Alphora has launched an AI‑powered software that predicts salt and co‑crystal formation for APIs and intermediates, developed in partnership with a local university. The machine‑learning platform is now a core component of its solid‑state screening programs, delivering highly...
VIDO – Six Years Later: How VIDO Helped Respond to the COVID-19 Pandemic
VIDO swiftly responded to COVID‑19 by designing a subunit vaccine candidate within days of the SARS‑CoV‑2 genome release, isolating the virus, and establishing animal models that enabled a Phase 1 human trial by early 2021, making it the first Canadian university...
Statement on Biomedical Countermeasures Initiative
BIOTECanada welcomes the launch of the National Research Council of Canada’s Biomedical Countermeasures Initiative, a key component of the federal Defence Industrial Strategy. The program is designed to strengthen Canada’s domestic capacity to develop and manufacture diagnostics, vaccines, and therapeutics...
Genomics Delegation to Boston – June 2026
The Canadian Genomics Strategy Secretariat, Global Affairs Canada and Genome Canada are organizing a genomics trade mission to Boston during the first week of June 2026, coinciding with the Festival of Genomics, Biodata and Artificial Intelligence. Selected Canadian genomics firms...